The Safety and Effectiveness of MK0476 (Montelukast) in Patients With Chronic Asthma (0476-388)

• Status: Completed
• Trial end date: 2008-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will test the safety and effectiveness of a range of doses of MK0476 (montelukast) compared to placebo on improved lung function in patients with chronic asthma.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Montelukast

Criteria

Inclusion Criteria:

• A person is 15 to 65 years of age. A person has had chronic asthma for at least one year

Exclusion Criteria:

• A person is a smoker or has smoked more that a pack a day for more than 10 years before stopping

• A person has other lung disorders such as COPD (chronic obstructive pulmonary disorder)